Lead sponsor
Eli Lilly and Company
51 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.
51
Trials led
12
Ongoing
31,212
Total enrollment
1,637
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
16
Phase 1/2
1
Phase 2
14
Phase 2/3
1
Phase 3
18
Not applicable
1
Trials by status
Recruiting
7
Active, not recruiting
5
Completed
33
Terminated
6
Trials led
TrialEligibility highlightPhaseStatusEnrollment
A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's DiseaseAlzheimer's diseaseN/ARecruiting6,250
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)Amyloid biomarker requiredPh 3Active, not recruiting2,996
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)MMSE 20-28Ph 3Active, not recruiting1,736
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)MMSE 20-30Ph 3Completed1,667
Effect of LY450139 on the Long Term Progression of Alzheimer's Diseasemild-to-moderate ADPh 3Completed1,537
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)MMSE 20-28Ph 3Active, not recruiting1,500
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)Amyloid biomarker requiredPh 3Active, not recruiting1,400
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)Amyloid biomarker required (PET)Ph 3Active, not recruiting1,175
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).Study partner/caregiver requiredPh 3Recruiting550
A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's DiseaseAge 60-85Ph 2Completed360
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)Dementia with Lewy bodiesPh 2Recruiting350
A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's DiseaseCDR global 0.5-1Ph 2Completed327
A Study of Mevidalen (LY3154207) in Participants With Alzheimer's DiseaseTau biomarker required (plasma)Ph 2Completed304
A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)MMSE 20-28Ph 2Completed272
Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's DiseaseAlzheimer's diseasePh 2Completed200
A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)MMSE 20-30Ph 3Completed148
Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's DiseaseAmyloid biomarker required (plasma)Ph 3Recruiting140
A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy ParticipantsMCI due to ADPh 1Completed139
Treatment for Aggression and Agitation in Patients With Alzheimer's DiseaseAlzheimer's diseasePh 2Completed132
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)early symptomatic ADPh 1Recruiting128
Adding Atomoxetine To Standard Medication Treatment In Patients With Alzheimer's DiseaseStudy partner/caregiver requiredPh 2/3Completed124
A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)Study partner/caregiver requiredPh 2Completed95
A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Diseasemild-to-moderate ADPh 1Completed94
A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)MCI due to AD / mild-to-moderate ADPh 1Completed72
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's DiseaseMCI due to ADPh 1/2Terminated70
A Study of LY3002813 in Participants With Alzheimer's DiseaseMCI due to AD / mild-to-moderate ADPh 1Completed63
A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or ADmild-to-moderate ADPh 1Completed61
A Biomarker Study of Solanezumab in Patients With and Without Alzheimer'sAlzheimer's diseasePh 2Completed55
A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)mild-to-moderate ADPh 1Terminated50
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's DiseaseTau biomarker required (PET)Ph 1Recruiting48
Effects of LY450139 Dihydrate on Subjects With Mild to Moderate Alzheimer's DiseaseAlzheimer's diseasePh 2Completed45
A Study of LY3372993 in Healthy Participants and Participants With Alzheimer's Disease (AD)mild-to-moderate ADPh 1Completed36
A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's DiseaseAlzheimer's diseasePh 1Completed36
Solanezumab Safety Study in Japanese Patients With Alzheimer's Diseasemild-to-moderate ADPh 2Completed33
A Study of Healthy Subjects to Assess the Effect of LY450139 on Amyloid Beta Peptide Production Rate and or Dose Response.Healthy volunteersPh 1Completed27
Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteersmild-to-moderate ADPh 2Completed25
A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Diseasemild-to-moderate ADPh 1Completed22